1. Home
  2. IMUX vs ENTX Comparison

IMUX vs ENTX Comparison

Compare IMUX & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • ENTX
  • Stock Information
  • Founded
  • IMUX 2016
  • ENTX 2010
  • Country
  • IMUX United States
  • ENTX Israel
  • Employees
  • IMUX N/A
  • ENTX N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • IMUX Health Care
  • ENTX Health Care
  • Exchange
  • IMUX Nasdaq
  • ENTX Nasdaq
  • Market Cap
  • IMUX 86.3M
  • ENTX 90.2M
  • IPO Year
  • IMUX N/A
  • ENTX 2018
  • Fundamental
  • Price
  • IMUX $1.00
  • ENTX $2.43
  • Analyst Decision
  • IMUX Strong Buy
  • ENTX Strong Buy
  • Analyst Count
  • IMUX 6
  • ENTX 1
  • Target Price
  • IMUX $12.67
  • ENTX $10.00
  • AVG Volume (30 Days)
  • IMUX 923.9K
  • ENTX 83.2K
  • Earning Date
  • IMUX 02-24-2025
  • ENTX 03-07-2025
  • Dividend Yield
  • IMUX N/A
  • ENTX N/A
  • EPS Growth
  • IMUX N/A
  • ENTX N/A
  • EPS
  • IMUX N/A
  • ENTX N/A
  • Revenue
  • IMUX N/A
  • ENTX $99,000.00
  • Revenue This Year
  • IMUX N/A
  • ENTX N/A
  • Revenue Next Year
  • IMUX N/A
  • ENTX N/A
  • P/E Ratio
  • IMUX N/A
  • ENTX N/A
  • Revenue Growth
  • IMUX N/A
  • ENTX 607.14
  • 52 Week Low
  • IMUX $0.92
  • ENTX $0.95
  • 52 Week High
  • IMUX $2.11
  • ENTX $3.35
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 50.39
  • ENTX 54.06
  • Support Level
  • IMUX $0.92
  • ENTX $2.21
  • Resistance Level
  • IMUX $0.97
  • ENTX $2.62
  • Average True Range (ATR)
  • IMUX 0.06
  • ENTX 0.21
  • MACD
  • IMUX 0.01
  • ENTX -0.01
  • Stochastic Oscillator
  • IMUX 66.61
  • ENTX 69.35

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Share on Social Networks: